Back to Search
Start Over
Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms.
- Source :
- Journal of Clinical Oncology, Vol. 40, no.Suppl 16, p. 9109 (2022)
- Publication Year :
- 2022
-
Abstract
- BACKGROUND : About 10% of EGFR mutations (EGFRm) are ‘uncommon mutations’ (ucEGFRm). osimertinib is a 3rd generation EGFRi, active against common EGFRm. We aimed to collect real-world data about systemic and brain response and resistance mechanisms to osimertinib for ucEGFRm patients.
Details
- Database :
- OAIster
- Journal :
- Journal of Clinical Oncology, Vol. 40, no.Suppl 16, p. 9109 (2022)
- Notes :
- English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1372937195
- Document Type :
- Electronic Resource